Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) announced in Q1 CY2025, but sales fell by 4.3% year on year ...

PacBio agreed to acquire Omniome for approximately $600 million upfront consisting of 9.4 million shares of PacBio common stock and $300 million in cash—plus up to $200 million in cash and stock ...

"Scale matters," says the new CEO. One of the goals of Illumina Inc.'s planned $1.2 billion buyout of PacBio three years ago was to capture a ready-built platform to help scientists peer into DNA ...

Pacific Biosciences of California (PACB) ended the recent trading session at $1.18, demonstrating a +1.72% change from the ...

PacBio and Intus Bio have launched GutID, the first commercial human gut health test, showcasing their collaboration and innovation in microbiome research. GutID utilizes PacBio's HiFi sequencing ...

PacBio has delivered its first Vega systems to Berry Genomics as part of an early access agreement aimed at developing and optimizing targeted assays for carrier, prenatal, and newborn screening ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, recently announced the availability of a new computational analysis method — Tandem Repeat Genotyping Tool (TRGT ...

Pacific Biosciences of California, Inc. MENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended ...

PacBio has recently introduced new products that are expected to drive strong growth and improve gross margins over the next four to five years. The new products are the materialization of the ...